CSPC Innovation Pharmaceutical's (SHE:300765) subsidiary, CSPC Jushi Biopharmaceutical, initiated the phase Ib/II clinical trial of SYS6090 injection as a treatment for hepatocellular carcinoma, according to a Shenzhen bourse filing on Wednesday.
The Chinese pharmaceutical company's shares slipped during Thursday's afternoon trade.
The open-label, multicenter clinical trial looks into the safety and efficiency of the drug as a combination therapy.